Ottawa - Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) ('Avivagen'), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce that it will be a presenter at the Annual Alpha North Capital Event organized by CEM Events (CEM.ca) which takes place in The Bahamas between March 25 - 27, 2022. The invite only conference introduces growth-stage companies to active top-level capital finance individuals through a day of scheduled one-on-one meetings and networking activities. Avivagen will be represented by Mr. Kym Anthony, CEO and Dr. Jamie Nickerson, President.
About Avivagen
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.
About OxC-beta Technology and OxC-beta Livestock
Avivagen's OxC-beta technology is derived from Avivagen discoveries about -carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Brazil, Australia, and Malaysia.
Avivagen's OxC-beta Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.
Contact:
Avivagen Inc.
Drew Basek
Director
Investor Relations
100 Sussex Drive, Ottawa
Ontario, Canada K1A 0R6
Phone: 416-540-0733
E-mail: d.basek@avivagen.com
Kym Anthony
Chief Executive Officer
100 Sussex Drive, Ottawa
Ontario, Canada
K1A 0R6 Head Office
Phone: 613-949-8164
Website: www.avivagen.com
(C) 2022 Electronic News Publishing, source ENP Newswire